PYC Therapeutics (PYC) AGM 2025 summary

Opening remarks and agenda

• Meeting opened by Rohan Hockings, acknowledging the outgoing chair and introducing new board members.

• Agenda included formal business, financial statements, board changes, a forward-looking presentation, and a Q&A session.

• Introduction included company overview, 2025 highlights, and a forward look to 2026.

Board and executive committee updates

• Two new directors joined: Professor Ian Constable, with deep scientific and commercialization experience, and Peter Coleman, bringing M&A and dual-listing expertise.

• Outgoing chair Alan Tribe was recognized for his pivotal role since 2018.

• Board renewal is ongoing, with plans to add further industry expertise in the coming year.

• CEO Rohan Hockings committed to remain through 2027.

• Management provided forecasts and outlined risks and uncertainties in line with ASX disclosures.

Overview of voting outcomes

• Remuneration report passed with 99.88% support.

• Professor Ian Constable's reelection approved with 99.79% support.

• Alan Tribe's reelection resolution withdrawn due to his retirement.

• All resolutions decided by poll, with results to be announced to the market.